Welcome to our dedicated page for PRESSURE BIOSCIENCES news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on PRESSURE BIOSCIENCES stock.
Pressure BioSciences, Inc. (PBIO) is a forefront life sciences company that focuses on the development and commercialization of an innovative platform technology known as Pressure Cycling Technology (PCT). This technology employs cycles of hydrostatic pressure, ranging from ambient to ultra-high levels (up to 35,000 psi and beyond), to precisely control biomolecular interactions, offering significant advancements in various scientific fields.
The company's core business revolves around leveraging PCT to enhance the analysis, study, and manipulation of biological samples. This technology has broad applications in areas such as protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies. By utilizing PCT, researchers and scientists can achieve higher yields, improved quality, and better consistency in their biological analyses.
Recently, PBIO has made notable strides with the introduction of its new consumer products business unit, Uncle Bud’s. In January 2024, the company kicked off with a substantial $252,000 shipment of its Sunburn Soother to one of the world’s largest retailers, showcasing strong market demand and consumer interest. Additionally, VICAR Holdings LLC has committed to purchasing over 10,000 bottles of PBIO's best-in-class Nano-CBD topical spray in 2024, indicating a promising trajectory for their consumer products segment.
PBIO's relocation to a new facility has significantly increased their manufacturing space, enhanced operating efficiencies, and achieved measurable cost savings, setting the stage for unencumbered growth through multi-year expansion plans. The new facility is expected to support the company's long-term strategy and scale operations to meet growing demand.
Uncle Bud's acquisition has already yielded early synergies and measurable performance metrics within the first month, boosting PBIO's market presence and consumer engagement. This positive momentum highlights PBIO's capability to integrate and scale operations effectively.
Furthermore, Pressure BioSciences’ UltraShear platform continues to showcase its potential by enabling the development and launch of health and wellness products with groundbreaking bioavailability, fast onset, and effectiveness. This platform technology is a testament to PBIO's commitment to innovation and enhancing the quality and effectiveness of bio-molecular research and consumer applications.
Pressure BioSciences, Inc. (OTCQB: PBIO) has announced the award of its second U.S. patent for its Ultra Shear Technology (UST) platform, increasing its intellectual property to seven UST patents worldwide. This new patent, which focuses on a compact valve with throttling capability, enhances the production of stable nanoemulsions, potentially transforming numerous industries such as pharmaceuticals, food, and cosmetics. The UST platform promises improved bioavailability, quality, and operational efficiency, aiming for strong sales growth and profitability in 2022.
Pressure BioSciences, Inc. (OTCQB: PBIO) announced a strategic expansion of its patented BaroFold technology platform, addressing challenges in the protein therapeutics market expected to reach $233 billion by 2027. The BaroFold platform offers a cost-effective solution to protein aggregation and misfolding issues, enhancing production efficiency. Over two years, PBI's BaroFold Services business has grown from one customer to four, serving both startups and multi-billion-dollar companies. The scalable technology improves processing yields and reduces time to market for protein-based therapeutics, presenting lucrative opportunities for the company.
Pressure BioSciences, Inc. (PBIO) will participate in Benzinga's ALL ACCESS Investor Event on November 4, 2021, at 11:20 am ET. CEO Richard T. Schumacher will present in a unique format that blends interviews with presentations. The company announced strong financial growth in recent quarters and expects further improvement for Q3/Q4 2021, alongside plans to acquire an eco-friendly agrochemical supplier. Recent innovations include a patented UST platform yielding stable products and collaborations with Ohio State University for the food industry.
Pressure BioSciences (OTCQB: PBIO) has successfully utilized its Ultra Shear Technology (UST) platform to create stable, water-miscible concentrates of neem oil, positioning itself in the eco-friendly pesticide market. These nanoemulsions not only maintain efficacy over time but also offer a consistent application, addressing concerns with traditional neem oil products. The estimated annual cost of invasive insect damage is $70 billion globally, and the use of neem oil is expected to reduce agricultural losses. PBI is exploring commercialization opportunities via its new subsidiary, PBI Agrochem.
Pressure BioSciences, Inc. (PBIO) announced plans for establishing demonstration and toll manufacturing sites on the U.S. East and West Coasts to enhance its Ultra Shear Technology (UST) applications for nanoemulsions. The company is in discussions with partners to accelerate product demonstrations and fulfill growing manufacturing demands, particularly from sectors like pharmaceuticals and nutraceuticals. Early feedback indicates significant interest in UST's capabilities, especially for hemp-derived products. PBIO aims to launch its UST systems by late 2021 or early 2022, targeting profitability by late 2022.
Pressure BioSciences, Inc. (OTCQB:PBIO) is set to present at the Benzinga Healthcare and Emerging Growth Small Cap Conferences. CEO Richard T. Schumacher will discuss the company's revenue growth in 2021, the anticipated commercial release of its Ultra Shear Technology™ platform, and its acquisition of eco-friendly agrochemical assets. The Emerging Growth Conference is on September 29, 2021, and the Benzinga Healthcare Conference is on September 30, 2021. PBI focuses on pressure-based solutions for various industries and aims to up-list to a national stock exchange.
Pressure BioSciences (PBIO) reported robust Q2 2021 financial results, with total revenue skyrocketing by 127% to $608,900, driven by a 178% rise in instrument sales. BaroFold/UST services surged 298%. The operating loss reduced by 51% to $646,300, improving net loss per share to $(0.90). For the first half, total revenue increased 124% to $1,168,800. The formation of PBI Agrochem is expected to unlock further growth, with over $1,000,000 in orders received in its first month. A positive outlook for Q3 and Q4 2021 is anticipated.
Pressure BioSciences, Inc. (PBIO) will hold a teleconference on August 19, 2021, at 4:30 PM ET to discuss its Q2 2021 financial results and ongoing business activities. The call will feature a presentation followed by a Q&A session. Interested parties can join via telephone or listen to a replay available after August 20, 2021. PBIO aims to leverage its pressure cycling technology for various applications, including biopharma contract services and food preservation, enhancing its market presence significantly.
Pressure BioSciences (OTCQB:PBIO) announced the successful launch of its eco-friendly agrochemical subsidiary, PBI Agrochem, Inc., which garnered over $1,000,000 in purchase orders in its first month. CEO Richard T. Schumacher will present at the Emerging Growth Conference on August 18, 2021, providing insights on this achievement and the company's strategy. The initial orders are expected to ship in Q3 2021, with the expectation of significant recurring revenue and profitability by 2022.
Pressure BioSciences (OTCQB: PBIO) has established its new agrochemicals subsidiary, PBI Agrochem, which has secured over $1M in initial purchase orders for eco-friendly agrochemical products. This initiative is expected to significantly enhance Q3 2021 revenues. The company plans to integrate PBI Agrochem into the supply chain of a planned acquisition of a global agrochemicals business, aiming for a major growth trajectory. PBI's management anticipates that strong early sales will lead to a potential doubling of quarterly revenues, paving the way towards profitability by the end of 2022.
FAQ
What is the current stock price of PRESSURE BIOSCIENCES (PBIO)?
What is the market cap of PRESSURE BIOSCIENCES (PBIO)?
What is Pressure BioSciences, Inc. (PBIO)?
What is Pressure Cycling Technology (PCT)?
In which areas is PCT technology applied?
What recent achievements has PBIO made?
What is Uncle Bud’s?
How has PBIO's new facility impacted the company?
What is the UltraShear platform?
How has Uncle Bud’s performed since its acquisition?
What are some applications of PBIO’s products?
What is the significance of PBIO’s consumer products?
